Comparison · NCT02322593-edc8fc84
TAS-118/Oxaliplatin vs S-1/Cisplatin: Overall Response Rate
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. TAS-118/Oxaliplatin vs S-1/Cisplatin: Overall Response Rate. Trial comparisons, record NCT02322593-edc8fc84. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02322593-edc8fc84
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.735 | 0.671 | 0.79 | wilson | |
| Risk in group 2 | 0.5 | 0.433 | 0.567 | wilson | |
| Risk difference, group 1 minus group 2 | 0.235 | 0.143 | 0.321 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.47 | 1.26 | 1.72 | log | |
| Odds ratio, group 1 over group 2 | 2.77 | 1.84 | 4.16 | log | |
| Number needed to treat, for one more participant with the outcome on TAS-118/Oxaliplatin than on S-1/Cisplatin | 4.26 | 3.11 | 7.01 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | TAS-118/Oxaliplatin | TAS-118 plus Oxaliplatin~L-OHP was administered intravenously at dose of 85 mg/m2 on day 1, and TAS-118 were administered 30-60 mg orally twice daily for 7 days (day 1 through day 7), repeated every 2 weeks. Treatment was continued during the study period unless any of Study Treatment Discontinuation Criteria was met. | 155 | 211 | OG000 |
| Group 2 | S-1/Cisplatin | S-1 plus Cisplatin~CDDP was administered intravenously at dose of 60 mg/m2 on day 1 (Korea) or day 8 (Japan), and S-1 were administered 40-60 mg orally twice daily for 21 days (day 1 through day 21), repeated every 5 weeks (rest period can be shorten from 14 days to 7 days). Treatment was continued during the study period unless any of Study Treatment Discontinuation Criteria was met. | 106 | 212 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Overall Response Rate
- Description
- ORR was defined as the proportion of patients with the best unconfirmed overall response of complete response (CR) or partial response (PR) in patients with measurable lesions
- Time frame
- From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 42 months.
- Population
Tumor Response (TR) Evaluable Population： Patients in FAS population presenting measurable lesions (at least one target lesion), evaluated for tumor responses at least once during treatment with the study drug.
Source ClinicalTrials.gov
Trial
- Title
- Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer
- NCT number
- NCT02322593
- Phases
- PHASE3
- Conditions
- Gastric Cancer
- Interventions
- TAS-118 plus Oxaliplatin, S-1 plus Cisplatin
- Lead sponsor
- Taiho Pharmaceutical Co., Ltd.
- Results first posted
- 2021-12-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02322593?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02322593-edc8fc84